Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
Conditions
Interventions
Dupilumab
Locations
84
United States
Regeneron Investigational Site
Birmingham, Alabama, United States
Regeneron Investigational Site
Gilbert, Arizona, United States
Regeneron Investigational Site
Bakersfield, California, United States
Regeneron Investigational Site
Long Beach, California, United States
Regeneron Investigational Site
Los Angeles, California, United States
Regeneron Investigational site
Mission Viejo, California, United States
Start Date
October 15, 2015
Primary Completion Date
October 7, 2026
Completion Date
October 7, 2026
Last Updated
June 26, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions